Organ transplantation has achieved impressive success rates over the last two to three decades, with over 90% of transplanted kidneys now surviving for at least 1 year. This has been achieved predominantly through the use of immunosuppressive drugs that efficiently control acute rejection. Nevertheless, transplantation still faces several major problems. First, lifelong immunosuppression is associated with toxicity, opportunistic infections and a high incidence of cancer (up to a seven-fold increase at 10 years after transplantation, with a tendency to increase with time). Second, despite immunosuppression, chronic rejection results in a high incidence of graft failure. For example, 10 years after transplantation, 50% of grafted kidneys have been rejected. Third, early graft loss due to cell death (independent of immune recognition) is a frequent problem in cellular and vascularized transplantion. Finally, the critical shortage of organ donors limits the opportunities for transplantation.
Solutions to some of these problems will come from the application of new strategies of immunointervention. These aim to obtain, at best, graft tolerance (which is defined as graft unresponsiveness in the absence of immunosuppressive drugs and chronic rejection), or at least a reduction in the required doses of immunoCorrespondence: I Anegon, INSERM U437, Nantes, France ations, gene therapy in transplantation offers several potential advantages. Gene transfer into the graft can be performed ex vivo, during the transit between the donor and the recipient, thus avoiding many of the hurdles encountered with in vivo gene transfer. Furthermore, the difficulties associated with immune responses to the gene transfer vectors and transient gene expression may be easier to overcome when gene therapy protocols are applied to transplantation than when applied to other clinical situations. The next century should witness a rapid increase in the application of gene therapy techniques to large animal pre-clinical models of transplantation and later to clinical trials. Gene Therapy (2000) 7, 14-19. suppressors. These regimes for achieving graft acceptance will rely on the control of immune responses by the administration of molecules derived from the immune system that act through natural pathways of immune inhibition. Gene transfer has several potential advantages over systemic administration for the delivery of these immunosuppressive bioreagents. Secreted proteins produced by the graft after gene transfer could produce local immunosuppressive effects, thus avoiding generalized immunosuppression. In contrast to secreted proteins, for which direct injection of the recombinant molecules could be an alternative, overexpression of membranebound molecules (such as FasL), of intracellular proteins (such as anti-apoptotic molecules) or of molecules that act over a very short range (such as nitric oxide (NO)) has until now only been obtained through genetic engineering of donor tissues. In addition, transplantation presents the opportunity to perform ex vivo gene transfer allowing to avoid many of the obstacles related to in vivo gene transfer that are observed in other clinical situations.
One of the potential solutions for organ shortage is xenotransplantation. The use of transgenic pigs as donors is one of the main therapeutic strategies for clinical xenotransplantation. Furthermore, the generation of transgenic animals of other species is useful for experimental studies of transplantation. Although transgenesis and gene transfer into somatic cells share several significant scientific and technical aspects, each of these strategies has its own particularities. To keep this review concise, 15 therefore, the generation of transgenic animals for xenotransplantation will not be discussed further.
Strategies for gene therapy in transplantation
The two major parameters that define the method used for gene transfer are the site of action of the molecule expressed (intracellular or membrane molecules, as opposed to secreted proteins, demand more efficient gene transfer procedures) and the target-cell characteristics (such as quiescent versus proliferating cells or expression of viral receptors). Over the last few years, almost every transplantable organ or tissue has been shown to be receptive to gene transfer by one or more of the currently available gene transfer vectors. In addition to this extensive literature, more recent data has been published (as briefly summarized below), in which therapeutic genes have been used to prolong graft survival. The two major approaches to this type of gene transfer can be defined as: (1) inhibiting anti-graft immune responses and (2) increasing graft protective mechanisms.
Inhibition of anti-graft immune responses
The aim of this strategy is to inhibit the initiation, development or effector phases of the anti-graft immune response. Before describing these strategies in detail, the principal features of graft rejection will be briefly discussed.
T cells, and more particularly CD4 + T cells, are key players in organ rejection through the orchestration of different amplification and effector mechanisms. 1 Full T cell activation and proliferation depend on several signals generated from the interaction of T cells and antigen presenting cells (APCs). The allogeneic major histocompatibility (MHC)-derived peptides expressed on APCs are recognized by the T cell receptor, which delivers some of the intracellular signals necessary for T cell activation. These signals alone are not sufficient for complete T cell activation and, in the absence of costimulatory signals or danger signals, may produce T cell unresponsiveness. The costimulatory signals required for T cell activation are mostly generated by the interaction of the CD28 molecules on T cells with the B7 molecules on APCs. B7 expression depends on the delivery of amplification signals by CD40 molecules on APCs, after interaction with CD40L on T cells. CD28-B7 and CD40-CD40L costimulatory systems are essential for the initiation and maintenance of T cell-dependent immune responses. Amplification of T cell responses and effector mechanisms (such as cellular cytotoxicity, alloantibody production, macrophage activation and generation of inflammatory mediators) requires the production of cytokines, and interaction of these cytokines with their receptors. Organ rejection has often been associated with increased expression of Type 1 cytokines (such as IL-2 or IFN␥) that stimulate antigen presentation and effector mechanisms. In contrast, immunointervention strategies that aim at inducing graft tolerance, usually either inhibit the production of Type 1 cytokines, or preferentially upregulate the production of Type 2 cytokines (such as IL-4, IL-10, or IL-13) or TGF␤. Graft infiltration by activated immune cells also necessitates interactions between adhesion molecules expressed by endothelial cells and leukocytes. Finally, immune responses need to be turned Gene Therapy off and this is carried out by several mechanisms which inhibit T cells and which operate at the later stages during the immune response. For example, CTLA4 molecules expressed on activated T cells interact with B7 molecules, and deliver inhibitory signals to T cells. Apoptosis of activated T cells, in which the Fas-FasL interaction plays a considerable role, can also turn off immune responses. All of the steps involved in controlling T cell activation are potential targets for immunosuppressive strategies through gene transfer.
Inhibition of anti-graft immune responses can be obtained by either performing gene transfer into: (a) the graft, or (b) the cells of the immune system. Gene transfer into the graft allows local production of immunomodulatory molecules that could create a microenvironment acting on the cells or molecules directly involved in graft recognition and destruction, thereby avoiding systemic side-effects on other immune or non-immune cells. Nevertheless, the absence of systemic immunosuppression has not been rigorously verified for each gene transfer protocol and may prove to be difficult to achieve for secreted molecules generated after gene transfer into vascularized grafts. Compared with the systemic administration of soluble proteins with a short half-life (such as cytokines or soluble receptors), continuous local production of immunomodulatory molecules might increase their bioavailability, consequently increasing therapeutic efficacy of the procedure and decreasing the associated cost. As an alternative to directly modifying the graft, genetically engineered cells have been co-transplanted with cellular grafts (for example pancreatic islets) to produce locally active immunosuppressive bioreagents. 2 When genetically engineering the immune system, gene transfer could either be targeted to bone marrow cells or the thymus to manipulate B or T lymphocyte selection, or could be targeted to secondary lymphoid organs to block antigen presentation. In several studies, gene transfer into bone marrow precursors, and to a lesser extent the thymus, has been performed before organ transplantation, with encouraging results. [3] [4] [5] [6] In contrast, secondary lymphoid organs are anatomically dispersed and have only recently been targeted using dendritic cells that have been previously modified by gene transfer. 7 Blockage of costimulatory signals Blockage of B7/CD28 interactions with the extracellular portion of CTLA4 linked to the Fc fragment of IgG (CTLA4Ig) has generally resulted in the prolonged survival of allogeneic vascularized and pancreatic islets, but not permanent acceptance of the grafts. Administration of anti-CD40L antibodies to block CD40L/CD40 interactions has also resulted in impressive rates of permanent graft acceptance in rodent and primate pre-clinical models. Gene transfer has only been described for CTLA4Ig, but gene transfer of CD40Ig could also represent a worthwhile approach for blocking graft rejection.
Adenovirus-mediated CTLA4Ig gene transfer in a model of liver allotransplantation in rats induced indefinite graft survival. 8 Although survival of a second grafted organ was specific for donor, but not third party grafts, generalized immunosuppression for other antigens could not be excluded, since high levels of circulating CTLA4Ig were also detected several weeks after transplantation. In a model of heart allotransplantation in rats, gene transfer into the myocardium with an adenoviral vector coding for CTLA4Ig produced indefinite graft survival in all recipients, whereas intravenous administration of recombinant CTLA4Ig only prolonged graft survival for up to 22 days after transplantation (manuscript in preparation). This gene transfer protocol resulted in high levels of circulating CTLA4Ig over a period of several months, and also inhibition of antigen-specific humoral immune responses. Nevertheless, recipients with long surviving grafts rejected skin and hearts from unrelated third party donors whereas second grafted hearts from donor origin were accepted. Furthermore, although spleen or graft infiltrating lymphocytes showed inhibited proliferative responses in vitro, lymph node cells showed normal proliferative responses. Taken together, these results indicate that not all immune responses or lymphoid compartments were suppressed by CTLA4Ig.
In contrast to vascularized organ transplantation, adenovirally transduced pancreatic islets expressing CTLA4Ig and transplanted under the kidney capsule, showed moderately prolonged graft survival (from 9.9 ± 2 days to 21 ± 2.2 days) in all recipients (manuscript in preparation). More importantly, islet survival after gene transfer of CTLA4Ig was comparable to that obtained by systemic administration of the recombinant protein and was associated with very low levels of circulating CTLA4Ig, as well as normal antigen-specific humoral immune responses. Although adenovirus-mediated gene transfer into the pancreatic islets of mice does not affect islet function and does not accelerate allograft rejection, 9 there is evidence of an anti-adenovirus immune response, 9 and it is possible that other species may show more deleterious immune reactions against adenoviral vectors. CTLA4Ig gene transfer into islets using particle bombardment, a non-immunogenic but less efficient method for gene transfer into pancreatic islets, when compared with adenoviral transfer, prolonged graft survival in approximately 50% of cases. 10 Overall, these studies indicate that blockage of costimulatory molecules by gene transfer can result in comparable or better outcomes than those obtained by injection of the recombinant proteins, probably due to better bioavailability of the proteins. In vascularized organ transplants, as opposed to cellular transplantation, gene transfer of CTLA4Ig has been associated with nonspecific inhibition of some but not all immune responses, which is similar to the inhibition observed following systemic administration of the protein.
Finally, donor dendritic cells transduced with adenoviruses coding for CTLA4Ig have shown decreased allogenicity and prolonged survival when injected in allogeneic recipients. 7 This interesting approach needs to be validated in association with organ transplantation.
Immunodeviation and anti-inflammatory cytokines Expression of Type 2 cytokines or TGF␤ has the potential to promote graft survival by inhibiting the production of Type 1 cytokines and blocking some APC and macrophage functions.
Direct injection of a plasmid encoding TGF␤1 into nonvascularized murine neonatal cardiac grafts, transplanted into adult mice, has been shown to double the allograft survival. 11 In this study, immunosuppression of the allogeneic responses was preferentially limited to the graft, since plasmid constructs injected at a distal site did not prolong graft survival. Furthermore, the levels of donorspecific cytotoxic T cells and IL-2-producing cells were reduced among graft infiltrating cells but not among splenocytes.
In a more clinically relevant model of vascularized rat heart transplantation, overexpression of TGF␤1 from direct myocardial injection of a recombinant adenovirus resulted in prolonged graft survival, with a high proportion of recipients showing indefinite graft survival. 12, 13 In this model, TGF␤1 gene transfer to a site distant to the graft did not prolong graft survival, 12 and local production of IFN␥, TNF␣ and inducible NO synthase (iNOS) was inhibited (unpublished results).
Gene transfer of the sequence encoding viral IL-10 has also resulted in prolonged allograft survival. Viral IL-10 is a cytokine derived from the Epstein-Barr viral genome that is homologous to cellular IL-10, but lacks some of the T cell immunostimulatory activities of this molecule. Retrovirus-or adenovirus-mediated gene transfer of viral IL-10 in a non-vascularized neonatal cardiac transplantation model has been shown to moderately prolong allograft survival.
14,15 Notably, these results have been reproduced in a vascularized cardiac transplantation model using a lipid-mediated gene transfer technique. 16 In this model, levels of alloantigen-specific cytotoxic T cells were decreased not only among the graft infiltrating cells, but also in the spleen, suggesting a more generalized immunosuppressive effect.
Cellular IL-10 has also been reported to promote permanent liver graft acceptance 17 and prolong cardiac allograft survival in rats. 18 In both cases, local rejection mechanisms were inhibited, although generalized systemic immunosuppression was not assessed.
MHC antigens
Although MHC molecules are the main targets for allorejection, exposure of the recipient to donor MHC antigens (such as donor bone marrow or blood, MHC molecules or MHC-derived peptides) in a non-immunogeneic antigen presentation context (ie absence of danger signals or costimulation) has been shown to promote graft acceptance. Donor bone marrow transplantation can promote graft acceptance but is associated with a risk of graft-versus-host disease (GVHD). Therefore, gene transfer of MHC genes of donor origin into the recipient's bone marrow cells provides a clear advantage. The high level of MHC polymorphism may not be an obstacle to this approach since it has been shown that the presentation of a single allelic product can result in inhibition of the recipient's response to the entire donor haplotype. 3 Furthermore, transplantation of organs from living donors means that recipient bone marrow cells expressing donor MHC molecules can be generated for infusion into the recipient, before graft transplantation.
Bone marrow transplantation of retrovirally transduced recipient bone marrow cells with donor MHC class I or class II antigens, 4, 5 has induced prolonged donorspecific organ survival. Graft survival has also been prolonged following ex vivo donor MHC class I gene expression in recipient fibroblasts transferred systemically into the graft recipients. 3 Allogeneic MHC class I molecule expression after in vivo plasmid-mediated gene transfer into the thymus, used in association with an anti-lymphocyte serum, has produced indefinite survival of rat liver allografts in the majority of recipients. 6 Transplantation of recipient bone marrow cells expressing donor molecules has been applied to xenotransplantation to induce anergy to the ␣Gal epitope. This epitope is the major target for preformed natural antibodies that mediate hyperacute rejection of vascularized xenografts. Retrovirus-mediated expression in bone marrow of the ␣(1-3)galactosyltransferase enzyme (responsible for the synthesis of the ␣Gal epitope), has been shown to block the production of anti-␣Gal antibodies. 19 
Molecules inducing apoptosis of immune cells
Expression by grafted tissues of molecules such as FasL, may promote graft tolerance by inducing apoptosis of graft-reactive T cells expressing Fas. Grafted tissues expressing FasL would mimic immune privileged tissues, such as the eyes or testicles, where expression of FasL by certain cell types plays an essential anti-inflammatory role.
Contradictory results on allograft survival have been obtained after transplantation of grafts expressing FasL. When islets were co-transplanted with syngeneic myoblasts expressing FasL, 2 or after particle bombardment with FasL expressing plasmids, 10 the survival of allogeneic pancreatic islets was prolonged. However, when FasL was overexpressed in islet cells using adenoviral vectors or islets derived from transgenic mice, 20 islets were rejected in an accelerated fashion due to massive granulocyte infiltration. In another study, transplantation of transgenic hearts expressing FasL also resulted in accelerated graft rejection in allogeneic and syngeneic recipients due to a massive granulocytic infiltrate. 21 On the other hand, transplantation of kidneys transduced with an adenovirus coding for FasL resulted in moderate prolongation of graft survival, with no evidence of a granulocytic infiltrate. 22 Overall, these results indicate that regulation of inflammation and immune responses by Fas and FasL is complex, and fundamental aspects of the basic biology of these molecules require further clarification. Immunoprivileged tissues express other immunosuppressive molecules (such as TGF␤), and the local immunoprivilege properties of these tissues may depend on their association with FasL. This suggests that co-expression of FasL or other such molecules in graft tissues may be immunosuppressive in the absence of granulocyte infiltration.
Increasing graft self-protective mechanisms These approaches involve gene transfer into the organs or cells to be transplanted. Several of these strategies take into consideration that organ rejection or acceptance involves several non-immune mechanisms. These nonimmune mechanisms result in local inflammatory reactions after ischemia reperfusion and also take place in subsequent tissue repair processes. For several molecules which have protective actions in these processes, only cells expressing the transgene and not unmodified adjacent cells will be protected. This implies that the success of these strategies depends on either introducing the genes to a very high proportion of the cells within a graft or on expressing secreted molecules containing a therapeutic moiety and peptide sequences which allow penetration into neighbouring cells.
Gene Therapy
Gene therapy for anti-oxidative stress A significant proportion of early non-immune loss in cellular transplants and vascularized grafts is due to anoxia and ischemia-reperfusion injuries that trigger the generation of reactive oxygen species. These reactive oxygen species are responsible for cell death within the graft, induced cytokine production and recruitment of leukocytes. Oxidative stress also increases the likelihood of subsequent acute and chronic rejection of vascularized grafts.
Intrastriatal transplantation of embryonic dopamine neurons, as a treatment for Parkinson's disease, is a representative example of cellular transplantation where 80-95% of grafted cells are estimated to be lost at an early stage. A role for oxidative-stress in this early neuron loss after transplantation was confirmed using adenovirusmediated expression of the copper-zinc superoxide dismutase gene in ex vivo transduced neurons. Rats transplanted with these neurons showed increased functional recovery following syngeneic transplantation. 23 Recently, the role of oxidative stress in the ischemiareperfusion injuries frequently observed in vascularized grafts, has been confirmed in the liver by using a gene transfer approach. 24 In this study, hepatocellular injury following ischemia-reperfusion was reduced by adenovirus-mediated overexpression of mitochondrial superoxide dismutase. This injury reduction was associated with inhibition of redox-mediated activation of NF-B and AP1 transcription factors. These results suggest that gene transfer of molecules that inhibit oxidoreduction can prevent organ dysfunction. Nevertheless, gene transfer in this study was performed 2 weeks before ischemiareperfusion injury, 24 a protocol still incompatible with clinical applications.
Anti-apoptotic and anti-proliferative genes Overexpression of anti-apoptotic genes by grafted cells is a key area of research in gene transfer in transplantation. This area covers not only the prevention of apoptosis as a consequence of ischemia-reperfusion injury, but also a reduction in the death of parenchymal cells as a result of the underlying disease (for example in several immune or non-immune liver diseases), or as a consequence of immune effector mechanisms active during graft rejection. This anti-apoptotic strategy has been applied to a model of subacute hepatic failure induced by the administration of anti-Fas antibodies. In this model, transplanted hepatocytes expressing the anti-apoptotic gene Bcl-2 derived from Bcl-2 transgenic mice, were resistant to apoptosis, repopulated the liver and prevented the animals from dying. 25 Furthermore, hepatocyte injury and apoptosis have also been prevented by adenovirusmediated gene transfer of Bcl-2 in a model of liver ischemia-reperfusion injury. 26 In vitro expression of anti-apoptotic genes (Bcl-2, BclxL and A20) by endothelial cells has also been shown not only to protect endothelial cells from apoptosis, but also to inhibit their activation through NF-kB dependent mechanisms. 27 Endothelial cell activation by cytokines or reactive oxygen species is mediated by NF-kB, and results in the production of many pro-inflammatory mediators that are likely to contribute to xenotransplant rejection. Therefore, the application of these findings is potentially important in xeno and allotransplantation. However, obstacles may arise resulting from the limited efficiency of current methods for gene transfer into the endothelium of allogeneic organs.
Chronic rejection marks the end stage of a high proportion of vascularized grafts. One of the main pathological features of cardiac chronic rejection is the appearance of an arteriopathy characterized by a diffuse intimal thickening resulting from the proliferation of vascular smooth muscle cells. In a rodent model of cardiac chronic rejection, inhibition of cyclin-dependent kinase 2 expression (an important enzyme in the transition from the G1-S phase of the cell cycle) prevented proliferation of smooth muscle cells and therefore intimal hyperplasia, and inhibited expression of cell adhesion molecules by endothelial cells. 28 This was attained by delivery of antisense oligodeoxynucleotides into the coronary arteries together with hemagglutinating virus of Japanliposome complexes. Similarly, adenovirus-mediated overexpression of iNOS in a model of aortic allograft rejection, inhibited intimal hyperplasia. 29 
Conclusions and future developments
The entire field of gene therapy, and in particular the application of gene transfer techniques to transplantation, are still in the early stages of development. In the next century, gene therapy has the potential to solve several of the major transplantation problems, although it must find its place among the other efficient immunosuppressive strategies already available. The future application of gene therapy to transplantation depends on improvements in: (1) gene transfer vectors and delivery protocols to obtain efficient transfection rates with minimal toxicity, and to spatially and temporally control transgene expression; and (2) the identification of molecular targets to reduce the very rapid cell death observed after transplantation, to achieve tolerance, and reduce chronic rejection.
Some of the major obstacles found in the application of gene therapy to other clinical situations may be less significant in the case of transplantation, such as immune responses to the gene transfer vectors and transient gene expression. The immune response to gene transfer vectors may be reduced by the expression of immunosuppressive genes used to suppress allogeneic immune responses. 15 Even if successful gene therapy protocols were developed for clinical transplantation, some form of immunosuppression would be required, further inhibiting the anti-vector immune responses. Finally, transient gene expression (as obtained with most of the gene transfer vectors) may even be desirable, since graft acceptance mechanisms can be established after short periods of therapeutic immunointervention.
Gene transfer of immunomodulatory genes has already proved to be a useful approach to manipulate the immune response and prolong graft survival in experimental transplantation. Although many of these approaches are in too early a stage of development to be applied in clinical trials, limited but encouraging clinical results have already been obtained using suicide gene therapy strategies to control GVHD after allogeneic bone marrow transplantation. 30 In these protocols, donor T cells transduced ex vivo with the suicide Herpes simplex virus type 1 thymidine kinase (tk) gene are infused together with T cell-depleted bone marrow. In the case of GHVD, subsequent administration of nucleoside analogues such as gancyclovir, selectively kills the proliferating TK + alloreactive T cells responsible for GVHD. Therefore, although gene transfer protocols are far from ideal, they are now suitable for application to large animal preclinical trials and later to clinical protocols. If the application of gene transfer is successfully developed in clinical transplantation, this will have a very significant impact upon the field of transplantation and may also extend the applications of transplantation to many acute and chronic pathologies.
